Article Information
History
- July 18, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Pedro Martínez-Fletaa,
- Arantzazu Alfrancaa,b,
- Isidoro González-Álvaroa,c,
- Jose M Casasnovasd,
- Daniel Fernández-Sotoe,
- Gloria Estesoe,
- Yaiza Cáceres-Martelle,
- Sofía Gardetae,
- Salomé Pratd,
- Tamara Mateu-Alberoa,
- Ligia Gabriea,
- Eduardo López-Granadosf,
- Francisco Sánchez-Madrida,b,
- Hugh T. Reyburne,*,
- José M. Rodríguez Fradee,* and
- Mar Valés-Gómeze,*
- aImmunology Department, Hospital Universitario La Princesa IIS-IP, Madrid, Spain
- bCIBER Cardiovascular
- cRheumatology Department. Hospital Universitario La Princesa. IIS-IP, Madrid, Spain
- dDepartment of Macromolecular structures, National Centre for Biotechnology, CNB-CSIC, Madrid, Spain CNB
- eDepartment of Immunology and Oncology, National Centre for Biotechnology, CNB-CSIC, Madrid, Spain
- fHospital Universitario La Paz, Madrid, Spain
- ↵*Corresponding authors:
Department of Immunology and Oncology, National Centre for Biotechnology, CNB-CSIC, Madrid, Spain. Tel. +34 91 585 4313; email: mvales{at}cnb.csic.es, jmrfrade{at}cnb.csic.es, htreyburn{at}cnb.csic.es
Posted July 18, 2020.
SARS-Cov-2 cysteine-like protease (Mpro) is immunogenic and can be detected in serum and saliva of COVID-19-seropositive individuals
